Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L A Beck

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Cell Death and Differentiation|January 16, 2016
ΔNp63 regulates IL-33 and IL-31 signaling in atopic dermatitisJ M Rizzo, A Oyelakin, S Min, et al.
The British Journal of Dermatology|August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitisA Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|November 3, 2019
The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection GroupH Alexander, A S Paller, C Traidl-Hoffmann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyK Reich, J I Silverberg, K A Papp, et al.
Cancer Research|April 15, 1997
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transferJ W Simons, E M Jaffee, C E Weber, et al.
The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Cell Death and Differentiation|January 16, 2016
ΔNp63 regulates IL-33 and IL-31 signaling in atopic dermatitisJ M Rizzo, A Oyelakin, S Min, et al.
The British Journal of Dermatology|August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitisA Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|November 3, 2019
The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection GroupH Alexander, A S Paller, C Traidl-Hoffmann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyK Reich, J I Silverberg, K A Papp, et al.
Cancer Research|April 15, 1997
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transferJ W Simons, E M Jaffee, C E Weber, et al.
The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.
Pageof 5